Page 5 - ஒருங்கிணைந்த பார்கின்சன் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Parkinson’s disease: new real-world data available on safinamide 28th April 2021 ADVERTISEMENT FEATURE   Dr Jason Raw outlines key findings from the SYNPASES trial, which explored the tolerability of safinamide used as an adjunct therapy in patients with Parkinson s disease Zambon has officially presented the results from SYNAPSES, its multinational, multicentre, retrospective/prospective cohort observational study that explored the tolerability of safinamide used as an adjunct therapy in 1,610 patients followed up to 12 months. The study was designed to include potentially all patients treated with safinamide as per clinical practice 1, and investigate the real-world use of safinamide in six European countries including the UK, particularly in patient populations not well represented in clinical trials such as those older than 75, those with psychiatric illnesses or those with relevant comorbidities.

Greater manchesterUnited kingdom generalUnited kingdomUnified parkinsonDisease rating scaleJason rawFairfield general hospitalRoutine clinicalParkinsons disRel disordஅதிகமானது மான்செஸ்டர்ஒன்றுபட்டது கிஂக்டம் ஜநரல்ஒன்றுபட்டது கிஂக்டம்ஒருங்கிணைந்த பார்கின்சன்நோய் ரேடிஂக் அளவுஃபேர்ஃபீல்ட் ஜநரல் மருத்துவமனை